Highland Capital Management (Texas)’s Aimmune Therapeutics AIMT Stock Holding History

Highland Capital Management (Texas)’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$506K	Hold	24,300	–	–	0.03%	252
2019 Q1	$543K	Hold	24,300	–	–	0.03%	239
2018 Q4	$581K	Sell	24,300 -269,860	-92%	-$6.98M	0.04%	190
2018 Q3	$8.03M	Buy	294,160 +5,360	+2%	+$152K	0.44%	59
2018 Q2	$7.77M	Buy	288,800 +45,500	+19%	+$1.39M	0.44%	58
2018 Q1	$7.74M	Buy	243,300 +93,550	+62%	+$3.29M	0.4%	67
2017 Q4	$5.66M	Buy	+149,750	New	+$4.83M	0.26%	91

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highland Capital Management (Texas)'s AIMT Position: Q2 2019 in Review

Highland Capital Management (Texas) held its Aimmune Therapeutics (AIMT) position steady in Q2 2019 at 24,300 shares worth $506K. The position accounts for 0.03% of the portfolio, ranked #252.

Highland Capital Management (Texas) first reported a position in AIMT in Q4 2017 and has held it in 7 quarters since. The position peaked at $8.03M in Q3 2018. 125 funds tracked by Wall St. Rank hold AIMT as of Q2 2019.

Highland Capital Management (Texas) held 24,300 shares of Aimmune Therapeutics worth $506K as of Q2 2019.
Highland Capital Management (Texas) left its Aimmune Therapeutics share count unchanged in Q2 2019.
Aimmune Therapeutics made up 0.03% of Highland Capital Management (Texas)'s portfolio in Q2 2019, its #252 holding.
Highland Capital Management (Texas) first reported a position in Aimmune Therapeutics in Q4 2017 and has held it in 7 quarters since.
Highland Capital Management (Texas)'s Aimmune Therapeutics position peaked at $8.03M in Q3 2018.
125 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2019.

Based on Highland Capital Management (Texas)'s 13F filing for Q2 2019, filed 14 Aug 2019.